Document is current
Any future updates will be listed below
-
Authors
Ndayisaba, Gilles
Yeka, Adoke
Asante, Kwaku Poku
Grobusch, Martin P.
Karita, Etienne
Mugerwa, Henry
Asiimwe, Stephen
Oduro, Abraham
Fofana, Bakary
Doumbia, Seydou
Jain, Jay Prakash
Barsainya, Sarita
Kullak-Ublick, Gerd A.
Su, Guoqin
Schmitt, Esther K.
Csermak, Katalin
Gandhi, Preetam https://orcid.org/0000-0003-1774-1369
Hughes, David
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03334747 at ClinicalTrials.govDocuments that mention this clinical trial
Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa
https://doi.org/10.1186/s12936-021-04009-1
-
Funding
Funding for this research was provided by:
Wellcome Trust (207813/Z/17/Z)
- License Information
-
More Information
Article History
Received: 12 August 2021
Accepted: 4 December 2021
First Online: 20 December 2021
Declarations
:
: The trial was conducted in Mali, Gabon, Ghana, Uganda, and Rwanda. The protocol and all amendments were reviewed by the Independent Ethics Committee or Institutional Review Boards for each centre. The trial was conducted according to ICH E6 Guidelines for Good Clinical Practice from the Declaration of Helsinki. Each patient gave written informed consent at screening, before any study specific procedure was performed.
: Not applicable.
: JPJ, SB, GKU, GS, EKS, KCR, PG, DH are employed by Novartis and shareholders of Novartis Pharma AG. The other authors declare no competing interests.
